High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis

Infectious Diseases of Poverty

Volumn 4, Issue 1, 2015, Pages

  Li, Ting ^a   Ziniel, Peter D ^b   He, Pan qing ^c   Kommer, Valerie P ^b   Crowther, Gregory J ^c   He, Min ^a   Liu, Qing ^a   Voorhis, Wesley C ^c   Williams, David L ^b   Wang, Ming Wei ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

High throughput screening; Inhibitor; Schistosomiasis; Thioredoxin glutathione reductase

Indexed keywords

ANTISCHISTOSOMAL AGENT; GLUTATHIONE REDUCTASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; THIOREDOXIN; ENZYME INHIBITOR; MOLECULAR LIBRARY; MULTIENZYME COMPLEX; OXIDOREDUCTASE; THIOREDOXIN GLUTATHIONE REDUCTASE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BIOMPHALARIA GLABRATA; CERCARIA; ENZYME ACTIVITY; FEMALE; HIGH THROUGHPUT SCREENING; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; STRUCTURE ACTIVITY RELATION; WORM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SENSITIVITY; ENZYMOLOGY; HUMAN; MOLECULAR LIBRARY; PRECLINICAL STUDY; PROCEDURES; REPRODUCIBILITY; STANDARDS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; PARASITIC SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHISTOSOMICIDES; SMALL MOLECULE LIBRARIES;

EID: 85006198873     PISSN: 20955162     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/s40249-015-0071-z     Document Type: Article

References (22)

1. King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn. 2008;4(1):65-79. doi: 10.1177/1742395307084407.
2. Hotez PJ, Engels D, Fenwick A, Savioli L. Africa is desperate for praziquantel. Lancet. 2010;376(9740):496-8. doi: 10.1016/S0140-6736(10)60879-3.
3. Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis. 2009;3(9), e485. doi: 10.1371/journal.pntd.0000485.
4. Domling A, Khoury K. Praziquantel and schistosomiasis. ChemMedChem. 2010;5(9):1420-34. doi: 10.1002/cmdc.201000202.
5. Cioli D, Basso A, Valle C, Pica-Mattoccia L. Decades down the line: the viability of praziquantel for future schistosomiasis treatment. Expert Rev Anti-Infect Ther. 2012;10(8):835-7. doi: 10.1586/eri.12.70.
6. Huang HH, Rigouin C, Williams DL. The redox biology of schistosome parasites and applications for drug development. Curr Pharm Des. 2012;18(24):3595-611.
7. Sayed AA, Cook SK, Williams DL. Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. J Biol Chem. 2006;281(25):17001-10. doi: 10.1074/jbc.M512601200.
8. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007;4(6):e206. doi: 10.1371/journal.pmed.0040206.
9. Alger HM, Williams DL. The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol. 2002;121(1):129-39.
10. Ross F, Hernandez P, Porcal W, Lopez GV, Cerecetto H, Gonzalez M, et al. Identification of thioredoxin glutathione reductase inhibitors that kill cestode and trematode parasites. PLoS One. 2012;7(4):e35033. doi: 10.1371/journal.pone.0035033.
11. Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, et al. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against Schistosomiasis. J Med Chem. 2009;52(20):6474-83. doi: 10.1021/Jm901021k.
12. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med. 2008;14(4):407-12. doi: 10.1038/nm1737.
13. Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, Thomas CJ, et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis. 2008;2(1):e127. doi: 10.1371/journal.pntd.0000127.
14. Zhang JH, Chung TD, Oldenburg KR. A Simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen. 1999;4(2):67-73.
15. Tucker MS, Karunaratne LB, Lewis FA, Freitas TC, Liang YS. Schistosomiasis. Current Protocols in Immunology edited by John E Coligan et al. 2013;103: Unit 19 1. doi: 10.1002/0471142735.im1901s103.
16. Stefanic S, Dvorak J, Horn M, Braschi S, Sojka D, Ruelas DS, et al. RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl Trop Dis. 2010;4(10):e850. doi: 10.1371/journal.pntd.0000850.
17. Basch PF. Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. J Parasitol. 1981;67(2):179-85.
18. Gasco A, Fruttero R, Sorba G, Di Stilo A, Calvino R. NO donors: Focus on furoxan derivatives. Pure Appl Chem. 2004;76(5):973-81. doi: 10.1351/pac200476050973.
19. Fruttero R, Crosetti M, Chegaev K, Guglielmo S, Gasco A, Berardi F, et al. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J Med Chem. 2010;53(15):5467-75. doi: 10.1021/Jm100066y.
20. Guidi A, Mansour NR, Paveley RA, Carruthers IM, Besnard J, Hopkins AL, et al. Application of RNAi to genomic drug target validation in Schistosomes. PLoS Negl Trop Dis. 2015;9(5):e0003801. doi: 10.1371/journal.pntd.0003801.
21. Lea WA, Jadhav A, Rai G, Sayed AA, Cass CL, Inglese J, et al. A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Assay Drug Dev Technol. 2008;6(4):551-5. doi: 10.1089/adt.2008.149.
22. Andrews P. A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Arzneimittelforschung. 1981;31(3a):538-41.